Inhibikase Therapeutics, Inc. — Revenue by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/5b120e32-a90c-4215-acc5-7304aa8468f8/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2024 | $0 | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-046096 |
| FY 2023 | $260.5k | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-037160 |
| FY 2022 | $123.4k | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-011133 |
| FY 2021 | $3.1M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-005203 |
| FY 2020 | $698.5k | 2020-01-01 – 2020-12-31 | evidence 0000950170-22-005203 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Inhibikase Therapeutics, Inc. — all facts · Net Income · Operating Income